Skip to main content
SpringerLink
Log in

Significance of histopatholoaical evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response(pCR) as endpoint

  • Review Article
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

In recent years, primary therapy has been used to improve the prognosis of patients with locally advanced breast cancer and to expand the indication for breast conserving treatment for patients with a relatively early stage of breast cancer. In addition, the therapeutic efficacy of primary therapy has been evaluated on the basis of pathological findings and pathological complete response (pCR) is considered to be a main target of primary therapy. The results of NSABP protocol B-18 and B-27, and the Aberdeen trials confirmed the prognostic significance of pCR in primary therapy and indicated the significance of minute pathological assessment. However, the criteria of pathological response is not yet universal, but the evaluation of the main invasive tumor, intraductal component and the regional lymph nodes, is thought to be necessary, shown by the "Histopathological Criteria for Assessment of Therapeutic Response in Breast Cancer" compiled by the Japanese Breast Cancer Society. Among these criteria, there exist methodological variations as to the evaluation of residual disease of intraductal carcinoma, thus some controversies exist. The presence of intraductal component might be negligible with regard to prognosis, but might be an important risk factor for local recurrence after breast conserving therapy. In the future, participation by the pathologist in the field of primary therapy for breast cancer will be a matter of course in most clinical studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

pCR:

Pathological complete response

cCR:

Clinical complete response

SD:

Stable disease

ER:

Estrogen receptor

PgR:

Progesterone receptor

References

  1. Danforth DN Jr, Lippman ME, McDonald H, Bader J, Egan E, Lampert M, Steinberg SM, Swain SM: Effect of preoperative chemotherapy on mastectomy for locally advanced breast cancer.Am Surg 56:6–11, 1990.

    PubMed  Google Scholar 

  2. Swain SM, Sorace RA, Bagley CS, Danforth DN Jr, Bader J, Wesley MN, Steinberg SM, Lippman ME: Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmestatic breast cancer.Cancer Res 47:3889–3994,1987.

    PubMed  CAS  Google Scholar 

  3. Bonadonna G, Veronesi U, Brambilla C, Ferrari L, Luini A, Greco M, Bartoli C, Coopmans de Yoldi G, Zucali R, Rilke F, Andreola S, Silvestrini R, Di Fronzo G, Valagussa P: Primary chemotherapy to avoid mastectomy in tumors with diameter of three centimeters ormore.J Natl Cancer Inst 82:1539–1545,1990.

    Article  PubMed  CAS  Google Scholar 

  4. Schick P, Goodstein J, Moor J, Butler J, Senter KL: Preoperative chemotherapy followed by mastectomy for locally advanced breast cancer.J Surg Oncol 22:278–282,1983.

    Article  PubMed  CAS  Google Scholar 

  5. Sorace RA, Bagley CS, Lichter AS, Danforth DN Jr, Wesley MW, Young RC, Lippman ME: The management of nonmetastatic locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.World J Surg 9:775–785, 1985.

    Article  PubMed  CAS  Google Scholar 

  6. Perloff M, Lenick J: Chemotherapy before and after mastectomy in stage IE breast cancer.Arch Surg 117:879–881,1982.

    PubMed  CAS  Google Scholar 

  7. Jacquillat C, Weil M, Baillet F, Borel C, Auclerc G, de Maublanc MA, House« M, Forget G, Thill L, Soubranne C, Khayat D: Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer.Cancer 66:119–129,1990.

    Article  PubMed  CAS  Google Scholar 

  8. Scholl SM, Fourquet A, Asselain B, Pierga JY, Vilcoq JR, Durand JC, Dorval T, Palangie T, Jouve M, Beuzeboc P, Garcio-Giralt E, Salmon RJ, de la Rochefor-diere A, Campana F, Pouillart P: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.Eur J Cancer 30A:645–652,1994.

    Article  PubMed  CAS  Google Scholar 

  9. Powles TJ, Hickish TF, Makris A, Ashley SE, O’Brien MER, Tidy VA, Casey S, Nash AG, Sacks N, Cosgrove D, MacVicar D, Fernando I, Ford HT: Rondomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.J Clin Oncol 13:547–552,1995.

    PubMed  CAS  Google Scholar 

  10. Kuerer HM, Newman LA, Buzdar AU, Dhingra K, Hunt KK, Buchholz TA, Binkley SM, Strom EA, Ames FC, Ross MI, Feig BW, McNeese MD, Horto-bagyi GN, Singletary SE: Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status.Cancer J Sci Am 4:230–236,1998.

    PubMed  CAS  Google Scholar 

  11. Frierson HF Jr, Fechner RE: Histologic grade of locally advanced infiltrating ductal carcinoma after treatment with induction chemotherapy.Am J Clin Pathol 102:154–157,1994.

    PubMed  Google Scholar 

  12. Honkoop AH, Pinedo HM, De Jong JS, Verheul HMW, Linn SC, Hoekman K, Wagstaff J, Van Diest PJ: Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer.Am J Clin Pathol 107:211–218,1997.

    PubMed  CAS  Google Scholar 

  13. Hortobagyi GN, Buzdar AU, Strom EA, Ames FC, Singletary SE: Primary chemotherapy for early and advanced breast cancer.Cancer Letters 90:103–109, 1995.

    Article  PubMed  CAS  Google Scholar 

  14. Rasbridge SA, Gillett CE, Seymour AM, Patel K, Richards MA, Rubens RD, Millis RR: The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in parimary breast carcinoma.British J Cancer 70:335–341,1994.

    CAS  Google Scholar 

  15. Moll UM, Chumas J: Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer.Pathol Res Pract 193:187–196,1997.

    PubMed  CAS  Google Scholar 

  16. De Lena M, Zucali R, Viganotti G, Valagussa P, Bonadonna G: Combined chemotherapy-radiotherapy approach in locally advanced (T3b-T4) breast cancer.Cancer Chemother Pharmacol 1:53–59,1978.

    Article  PubMed  Google Scholar 

  17. Hortobagyi GN, Blumenschein GR, Spanos W, Mon-tague ED, Buzdar AU, Yap HY, Schell F: Multimodal treatment of locoregionally advanced breast cancer.Cancer 51:763–768,1983.

    Article  PubMed  CAS  Google Scholar 

  18. Jacquillat CL, Baillet F, Weil M, Auclerc G, Housset M, Auclerc MF, Sellami M, Jindani A, Thill L, Soubrane CL, Khayat D: Results of conservative treatment combining induction (neoadjuvant) and consolidation chemotherapy, hormonotherapy, and external and interstitial irradiation in 98 patients with locally advanced breast cancer (HA-MB).Cancer 61:1977–1982,1988.

    Article  PubMed  CAS  Google Scholar 

  19. Ragaz J, Knowling M, Jones G: Comparability of preopertive (neoadjuvant) (pre) and postoperative (post) therapy for locally advanced breast cancer (LABC).Proc Annu Meet Am Assoc Cancer Res 28:197 (abstract), 1987.

    Google Scholar 

  20. Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol 15:2483–2493,1997.

    PubMed  CAS  Google Scholar 

  21. Bear GS: Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.Surg Clin North Am 83:943–971, 2003.

    Article  PubMed  Google Scholar 

  22. Olson JE, Gray R, Sponzo RW, Damsker JI, Tormey DC, Cummings FJ: Management of nonresectable locally advanced (Stage II) breast cancer. An ECOG trial.Breast Cancer Res Treat 8:109 (abst.124), 1986.

    Google Scholar 

  23. Mauriac L, Durand M, Avil A, Dilhuydy JM: Effect of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm.Ann Oncol 2:347–354,1991.

    PubMed  CAS  Google Scholar 

  24. Mauriac L, MacGrogan G, Avil A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F on behalf of Institut Bergonie Bordeaux Groupe Sein (IBBGS): Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomised trial with a 124-month median follow-up.Ann Oncol 10:47–52,1999.

    Article  PubMed  CAS  Google Scholar 

  25. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, Margolese R, Theoret H, Soran A, Wickerham DL, Wolmark N; National Surgical Adjuvant Breast and Bowel Project Protocol B-27: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.J Clin Oncol 21:4165–4174,2003.

    Article  PubMed  CAS  Google Scholar 

  26. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O; Aberdeen Breast Group: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial.Clin Breast Cancer 2:S69–74, 2002.

    Article  Google Scholar 

  27. Frabzen S, Zajicek J: Aspiration biopsy in diagnosis of palpable lesions of the breast.Acta Radiol 7:241–262, 1968.

    Google Scholar 

  28. Smith IC, Miller ID: Issues involved in research into the neoadjuvant treatment of breast cancer.Anti-Cancer Drugs 12:525–529,2001.

    Article  Google Scholar 

  29. Parker SH, Lovin JD, Jobe WE, Burke BJ, Hopper KD, Yakes WF: Nonpalpable breast lesions; stereotactic automated large-core biopsies.Radiology 180:403–407, 1991.

    PubMed  CAS  Google Scholar 

  30. Kurosumi M, Akiyama F, Iwase T, Motomura K, Okazaki M, Tsuda H: Histopathological criteria for assessment of therapeutic response in breast cancer.Breast Cancer 8:1–2, 2001.

    Article  PubMed  CAS  Google Scholar 

  31. Matsuo K, Fukutomi T, Watanabe T, Hasegawa T, Tsuda H, Akashi-Tanaka S: Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas.Breast Cancer 9:75–81,2002.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Saitama Cancer Center, 818 Komuro, Ina-machi, Kitaadachi-gun, 362-0806, Saitama, Japan

    Masafumi Kurosumi

Authors
  1. Masafumi Kurosumi
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Kurosumi, M. Significance of histopatholoaical evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response(pCR) as endpoint. Breast Cancer 11, 139–147 (2004). https://doi.org/10.1007/BF02968293

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02968293

Key words

Search

Navigation